Q-omics provides the consensus-scored ZBTB22 profile across patient tissues and cancer cell-line models. ZBTB22 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ZBTB22 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, ZBTB22 RNA expression shows 19,727 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, LUAD, and ACC as cancer lineages where ZBTB22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB22 survival associations across molecular data types. ZBTB22 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB22 RNA expression–survival associations across cancer types. High ZBTB22 expression shows unfavorable associations in COAD and ACC, but favorable associations in KIRC, ESCA, THYM and READ. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ZBTB22 RNA expression.
This table summarizes ZBTB22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB22 shows lower tumor expression in LUAD, KICH, COAD and THCA and higher tumor expression in LIHC and HNSC. The LUAD box plot shows higher ZBTB22 RNA expression in normal versus tumor tissue (log2 FC = −0.673, t-test p < 0.001).
This table shows molecular features associated with ZBTB22 in patient tissues and cancer cell lines. In patient samples, ZBTB22 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
